MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -130.70K | -2.00K | -2.00K | 413.60K | 128.70K |
| Total Revenue | -130.70K | -2.00K | -2.00K | 413.60K | 128.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -130.70K | -2.00K | -2.00K | 413.60K | 128.70K |
| SG&A Expenses | 340.90K | 344.70K | 384.40K | 2.15M | 2.15M |
| Depreciation & Amortization | 25.90K | -400.00 | -400.00 | 9.90K | -400.00 |
| Other Operating Expenses | 17.80K | 17.80K | 31.90K | 31.90K | 31.90K |
| Total Operating Expenses | 384.50K | 362.00K | 415.80K | 2.19M | 2.18M |
| Operating Income | -515.20K | -364.00K | -417.80K | -1.78M | -2.06M |
| Income Before Tax | -404.10K | -180.20K | -273.10K | -2.37M | -2.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.40 | -0.18 | -0.27 | -2.37 | -2.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.40K | -400.00 | 200.00 | 200.00 | 200.00 |
| Net Income | -401.70K | -180.60K | -272.90K | -2.37M | -2.63M |
| EBIT | -515.20K | -364.00K | -417.80K | -1.78M | -2.06M |
| EBITDA | 40.90K | 194.70K | 194.70K | 194.70K | -89.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 537.89M | 502.92M | 479.07M | 693.95M | 591.64M |
| Average Diluted Shares Outstanding | 537.89M | 502.92M | 479.07M | 693.95M | 591.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
